Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. De plus, nous expédions CYP2C9 Kits (24) et CYP2C9 Protéines (4) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 57 products:
Human Monoclonal CYP2C9 Primary Antibody pour WB - ABIN1882233
Yang, Cui, Hasi, Jia, Gong, Su: Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. dans Genetics and molecular research : GMR 2010
Show all 3 Pubmed References
Human Polyclonal CYP2C9 Primary Antibody pour Func, IHC (fro) - ABIN2473172
Gilhodes, Gurfinkel, Roll: Role of Ia muscle spindle afferents in post-contraction and post-vibration motor effect genesis. dans Neuroscience letters 1992
Show all 4 Pubmed References
CYP2C9 mutations had a significant impact on 2-propyl-4-pentenoic acid concentration
We compared the carrier frequency of Cytochrome P450 (Montrer CYP Anticorps) Enzymes and Transport Proteins markers among the Russian population living in Moscow with Dagestan ethnic groups. Statistically significant differences for the following gene polymorphisms: CYP2C19 (Montrer CYP2C19 Anticorps)*17, CYP2C9*3, ABCB1 (Montrer ABCB1 Anticorps) (C3435T), SLCO1B1 (Montrer SLCO1B1 Anticorps)*5 were found between the Russian population and the three ethnic groups of the Dagestan republic.
Angiotensin II receptor blockers exhibit different degrees of inhibition of the metabolism of arachidonic acid by recombinant CYP2C9, CYP2J2 (Montrer CYP2J2 Anticorps) and liver microsomes.
analysis of VKORC1 (Montrer VKORC1 Anticorps) AA-CYP2C9*1*1 genotypes reveals dosing algorithms for vitamin K antagonists
In Silico Predictions of Drug - Drug Interactions Caused by CYP1A2 (Montrer CYP1A2 Anticorps), 2C9 and 3A4 Inhibition - a Comparative Study of Virtual Screening Performance
To investigate whether the CYP2C9*2 and *3 variants modify benzodiazepine-related fall risk. CYP2C9*2 and *3 allele variants modify benzodiazepine-related fall risk. Those using benzodiazepines and having reduced CYP2C9 enzyme activity based on their genotype are at increased fall risk.
In an Indian population of children with epilepsy on phenytoin monotherapy, CYP2C9*1, *2 & *3 allelic frequencies were 85.4, 4.5 and 10.1 % respectively. CYP2C9*3 allelic group showed significantly higher serum phenytoin levels compared to the wild variants.
The genotype distributions of the CYP2C9*3, CYP2D6 (Montrer CYP2D6 Anticorps)*10, and CYP3A5 (Montrer CYP3A5 Anticorps)*3 genetic polymorphisms were associated with the warfarin maintenance dose.
CYP2C9*2 and CYP2C9*3 genetic polymorphisms are associated with reduced S-warfarin oral clearance in healthy subjects
Case Report: time course of CYP2C9 deinduction appeared to be delayed compared to CYP3A after discontinuation of rifampicin therapy.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase